PRMT5 and prostate cancer: In the context of prostate cancer, BHLHE22 and PRMT5 assemble a transcriptional complex that initiates CSF2 transcription, which then attracts many immunosuppressive neutrophils and monocytes, promoting the tumor’s metastasis to the bones.